Nicole Onetto

Nicole Onetto, M.D., is an independent consultant in oncology, drug development, and translational research. She is currently on the board of directors for Viracta Therapeutics, Basilea Pharmaceutica and Bolt Biotherapeutics, and previously held director roles at NBE Therapeutics, Sierra Oncology, and ImmunoGen. She was Deputy Director and Chief Scientific Officer at the Ontario Institute for Cancer Research from 2009 to 2016. Prior to that, Dr. Onetto held the role of Chief Medical Officer at ZymoGenetics (Bristol Myers Squibb) and at OSI Pharmaceuticals (Astellas). Her career also includes senior management positions at Bristol Myers Squibb, Nexstar Pharmaceuticals (Gilead) and Immunex Corporation (Amgen). Dr. Onetto earned her bachelor’s degree from the University of Paris, a master’s degree in Pharmacology from the University of Montréal, and her medical degree and a Hematology-Oncology Certificate from the University of Paris.


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Bolt Biotherapeutics

7 followers

Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.


Industries

Employees

51-200

Links